| Dr Betsy J Furukawa, MD | |
|
2401 S 31st St, Temple, TX 76508-0001 | |
| (254) 724-2111 | |
| Not Available |
| Full Name | Dr Betsy J Furukawa |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 18 Years |
| Location | 2401 S 31st St, Temple, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275714545 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | A140309 (California) | Secondary |
| 207N00000X | Dermatology | 35495 (South Carolina) | Secondary |
| 207N00000X | Dermatology | N3038 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White Pavilion - Temple | Temple, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scott And White Clinic | 8123923604 | 2131 |
News Archive
An examination of the world-wide use of hematopoietic stem cell transplantation, which involves transplantation of blood stem cells derived from the bone marrow or blood, finds that there are significant differences in transplant rates between countries and continental regions by indication and donor type, and that HSCT is most frequently used in countries with higher gross national incomes and governmental health care expenditures, according to a study in the April 28 issue of JAMA.
Genoptix, Inc. announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") applicable to the cash tender offer by Novartis to purchase all outstanding shares of common stock of Genoptix at USD$25.00 per share.
Heart failure patients often have trouble with thinking and depression. A new study by University of Guelph researchers explains why and points to ways to prevent and treat both heart and brain maladies through the emerging field of circadian medicine.
Infection has been reduced up to 70% as of May 1st. Thanks to the developed model, scenarios can be drawn regarding future containment measures.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
› Verified 1 days ago
| Entity Name | Scott & White Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093779704 PECOS PAC ID: 8123923604 Enrollment ID: O20031223000640 |
News Archive
An examination of the world-wide use of hematopoietic stem cell transplantation, which involves transplantation of blood stem cells derived from the bone marrow or blood, finds that there are significant differences in transplant rates between countries and continental regions by indication and donor type, and that HSCT is most frequently used in countries with higher gross national incomes and governmental health care expenditures, according to a study in the April 28 issue of JAMA.
Genoptix, Inc. announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") applicable to the cash tender offer by Novartis to purchase all outstanding shares of common stock of Genoptix at USD$25.00 per share.
Heart failure patients often have trouble with thinking and depression. A new study by University of Guelph researchers explains why and points to ways to prevent and treat both heart and brain maladies through the emerging field of circadian medicine.
Infection has been reduced up to 70% as of May 1st. Thanks to the developed model, scenarios can be drawn regarding future containment measures.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Betsy J Furukawa, MD Po Box 844658, Dallas, TX 75284-4658 Ph: () - | Dr Betsy J Furukawa, MD 2401 S 31st St, Temple, TX 76508-0001 Ph: (254) 724-2111 |
News Archive
An examination of the world-wide use of hematopoietic stem cell transplantation, which involves transplantation of blood stem cells derived from the bone marrow or blood, finds that there are significant differences in transplant rates between countries and continental regions by indication and donor type, and that HSCT is most frequently used in countries with higher gross national incomes and governmental health care expenditures, according to a study in the April 28 issue of JAMA.
Genoptix, Inc. announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") applicable to the cash tender offer by Novartis to purchase all outstanding shares of common stock of Genoptix at USD$25.00 per share.
Heart failure patients often have trouble with thinking and depression. A new study by University of Guelph researchers explains why and points to ways to prevent and treat both heart and brain maladies through the emerging field of circadian medicine.
Infection has been reduced up to 70% as of May 1st. Thanks to the developed model, scenarios can be drawn regarding future containment measures.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
› Verified 1 days ago
Dr. Mark Grogan Tusa, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 409 W Adams Ave, Temple, TX 76501 Phone: 254-742-3775 | |
Dr. David Ford Butler, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 409 W Adams Ave, Temple, TX 76501 Phone: 254-742-3775 | |
Natalie Brittan Lane, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Katelen Korty, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Saadeddine S Saad, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St # Ms 01161b, Temple, TX 76508 Phone: 254-724-8797 | |
Cecil Jordan Staples, MD Dermatology Medicare: Medicare Enrolled Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 |